Molecular Imaging of Primary Amyloid Cardiomyopathy

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 171 participants.

Also called NCT02641145

  • Study
  • In this atlas

Overview

Design
Interventional study; non-randomized; no masking; primary purpose diagnostic
Phase
Not applicable
Enrolled
  • 171 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT02641145
Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT02641145. Non-randomized; no masking; primary purpose diagnostic. Start 2016-04-01 (registry gives no type); primary completion 2027-12-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Molecular Imaging of Primary Amyloid Cardiomyopathy
Acronym
MICA
Condition
Amyloidosis, Primary
Condition
Cardiomyopathy
Intervention (Radiation)
F-18 florbetapir/C-11 acetate PET
Intervention (Device)
MRI
Intervention (Radiation)
N-13 ammonia PET
Lead sponsor
Brigham and Women's Hospital (class: other)
Collaborator
National Institutes of Health (NIH) (class: US National Institutes of Health)
Collaborator
National Heart, Lung, and Blood Institute (NHLBI) (class: US National Institutes of Health)
Collaborator
American Heart Association (class: other)

Record details

Record id
cardio:ct-nct02641145
Content hash
8aec755669cc17e5b3c4b9e9953a996ecad36b5f1d929474825f8c2bd6b1adc2